Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study.
about
Use of self-controlled designs in pharmacoepidemiologyMuscle uncoupling protein 3 expression is unchanged by chronic ephedrine/caffeine treatment: results of a double blind, randomised clinical trial in morbidly obese females.Dietary intervention restored menses in female athletes with exercise-associated menstrual dysfunction with limited impact on bone and muscle health.Potential for bias in case-crossover studies with shared exposures analyzed using SASEfficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical TrialA systems biology-based investigation into the pharmacological mechanisms of wu tou tang acting on rheumatoid arthritis by integrating network analysis.Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safetyCase-crossover study design in pharmacoepidemiology: systematic review and recommendations.Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology.The effect of leptin, caffeine/ephedrine, and their combination upon visceral fat mass and weight loss.Register-based research: some methodological considerations.Pharmacokinetic determination of ephedrine in Herba Ephedrae and Wu Tou Tang decoctions in rats using ultra performance liquid chromatography tandem mass spectrometry.Combination pharmaceutical therapies for obesityStudy to Probe Subsistence of Host-Guest Inclusion Complexes of α and β-Cyclodextrins with Biologically Potent Drugs for Safety Regulatory Dischargement
P2860
Q26822935-7034101C-328D-4F2A-B16A-C30FD508869AQ33721244-4FE23385-6EEB-48ED-A737-BE98FAD12C3DQ34091710-3B453E9A-571C-4223-AAF1-E88ACA457C35Q35097908-C948BB8B-A20A-4088-8404-4F2F47072B5BQ35895759-5534883C-5932-4B75-949B-DEA4E58E51FCQ36763376-F4533B46-F43B-4F37-A9EC-F9DBCA07207CQ37178285-9267657E-6199-47BC-9271-4956CA7F1690Q37459724-6BD4E723-11F1-4864-B521-35E1DA968113Q38137002-97716D96-B42B-4078-A603-BA4D8D93C298Q39250149-5E9CD887-99A3-4237-B0E3-550675091D42Q47234580-D8F73B04-C1E4-400F-B385-DE6CFC944544Q50112056-A2DB4B90-1D57-4030-AC08-010598C0E671Q51419300-93A96E36-A45C-4609-8848-3F292CE82545Q57314317-738A0427-FCFC-4D2A-82B9-0CECE0A87917Q58695718-9809D02B-DAB8-4AF5-817B-F55FDABB37DE
P2860
Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@ast
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@en
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@nl
type
label
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@ast
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@en
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@nl
prefLabel
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@ast
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@en
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@nl
P2860
P50
P356
P1476
Use of a prescribed ephedrine/ ...... ry-based case-crossover study.
@en
P2860
P304
P356
10.1093/AJE/KWN191
P407
P577
2008-08-27T00:00:00Z